临床医学硕士论文参考文献一
[1] PORTER J R, RUCKH T T, POPAT K C. Bone tissue engineering: Areview in bone biomimetics and drug delivery strategies [J].Biotechnology progress, 2009, 25:1539-1560.
[2] KURTZ S M, ONG K L, SCHMIER J, et al. Future clinical and economicimpact of revision total hip and knee arthroplasty [J]. The Journal of boneand joint surgery. American volume, 2007, 89 Suppl 3:144-151.
[3] XU X, ZHANG K, ZHAO L, et al. Characteristics of three sizes of silicananoparticles in the osteoblastic cell line, MC3T3-E1 [J]. RSC Adv., 2014,4:46481-46487.
[4] NIE H, HO M L, WANG C K, et al. Bmp-2 plasmid loaded plga/hapcomposite scaffolds for treatment of bone defects in nude mice [J].Biomaterials, 2009, 30:892-901.
[5] KOLAR P, SCHMIDT-BLEEK K, SCHELL H, et al. The early fracturehematoma and its potential role in fracture healing [J]. Tissue engineering.Part B, Reviews, 2010, 16:427-434.
[6] ORYAN A, MOSHIRI A, MEIMANDI-PARIZI A. Implantation of anovel tissue-engineered graft in a large tendon defect initiatedinflammation, accelerated fibroplasia and improved remodeling of thenew achilles tendon: A comprehensive detailed study with new insights[J]. Cell and tissue research, 2014, 355:59-80.
[7] FERGUSON C, ALPERN E, MICLAU T, et al. Does adult fracture repairrecapitulate embryonic skeletal formation? [J]. Mechanisms ofdevelopment, 1999, 87:57-66.
[8] SIMON A M, MANIGRASSO M B, O'CONNOR J P. Cyclo-oxygenase 2function is essential for bone fracture healing [J]. Journal of bone andmineral research : the official journal of the American Society for Boneand Mineral Research, 2002, 17:963-976.
[9] DESCHASEAUX F, PONTIKOGLOU C, SENSEBE L. Boneregeneration: The stem/progenitor cells point of view [J]. Journal ofcellular and molecular medicine, 2010, 14:103-115.
[10] THOMAS M V, PULEO D A. Infection, inflammation, and boneregeneration: A paradoxical relationship [J]. Journal of dental research,2011, 90:1052-1061.
[11] OFFENBACHER S, ODLE B M, GREEN M D, et al. Inhibition ofhuman periodontal prostaglandin E2 synthesis with selected agents [J].Agents and actions, 1990, 29:232-238.
[12] OFFENBACHER S, HEASMAN P A, COLLINS J G. Modulation of hostPGE2 secretion as a determinant of periodontal disease expression [J].Journal of periodontology, 1993, 64:432-444.
[13] PRESHAW P M, HEASMAN P A. Prostaglandin E2 concentrations ingingival crevicular fluid: Observations in untreated chronic periodontitis[J]. Journal of clinical periodontology, 2002, 29:15-20.
[14] RAISZ L G. Prostaglandins and bone: Physiology and pathophysiology[J]. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society,1999, 7:419-421.
[15] WILLIAMS R C, JEFFCOAT M K, KAPLAN M L, et al. Flurbiprofen: Apotent inhibitor of alveolar bone resorption in beagles [J]. Science, 1985,227:640-642.
[16] WILLIAMS R C, JEFFCOAT M K, HOWELL T H, et al. Altering theprogression of human alveolar bone loss with the non-steroidalanti-inflammatory drug flurbiprofen [J]. Journal of periodontology, 1989,60:485-490.
[17] WEBER H P, FIORELLINI J P, PAQUETTE D W, et al. Inhibition ofperi-implant bone loss with the nonsteroidal anti-inflammatory drugflurbiprofen in beagle dogs. A preliminary study [J]. Clinical oralimplants research, 1994, 5:148-153.
[18] HARTEN R D, SVACH D J, SCHMELTZER R, et al. Salicylicacid-derived poly(anhydride-esters) inhibit bone resorption and formationin vivo [J]. Journal of biomedical materials research. Part A, 2005,72:354-362.
[19] REYNOLDS M A, PRUDENCIO A, AICHELMANN-REIDY M E, et al.Non-steroidal anti-inflammatory drug (NSAID) - derived poly(anhydride- esters) in bone and periodontal regeneration [J]. Current drug delivery,2007, 4:233-239.
[20] FULLER K, CHAMBERS T J. Effect of arachidonic acid metabolites onbone resorption by isolated rat osteoclasts [J]. Journal of bone andmineral research : the official journal of the American Society for Boneand Mineral Research, 1989, 4:209-215.
[21] CHAMBERS T J, FOX S, JAGGER C J, et al. The role of prostaglandinsand nitric oxide in the response of bone to mechanical forces [J].Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society,1999, 7:422-423.
[22] HARDER A T, AN Y H. The mechanisms of the inhibitory effects ofnonsteroidal anti-inflammatory drugs on bone healing: A concise review[J]. Journal of clinical pharmacology, 2003, 43:807-815.
[23] GERSTENFELD L C, AL-GHAWAS M, ALKHIARY Y M, et al.Selective and nonselective cyclooxygenase-2 inhibitors and experimentalfracture-healing. Reversibility of effects after short-term treatment [J].The Journal of bone and joint surgery. American volume, 2007,89:114-125.
[24] VUOLTEENAHO K, MOILANEN T, MOILANEN E. Non-steroidalanti-inflammatory drugs, cyclooxygenase-2 and the bone healing process[J]. Basic & clinical pharmacology & toxicology, 2008, 102:10-14.
[25] HAVEMOSE-POULSEN A, HOLMSTRUP P. Factors affectingil-1-mediated collagen metabolism by fibroblasts and the pathogenesis ofperiodontal disease: A review of the literature [J]. Critical reviews in oralbiology and medicine : an official publication of the AmericanAssociation of Oral Biologists, 1997, 8:217-236.
[26] GRAVES D. Cytokines that promote periodontal tissue destruction [J].Journal of periodontology, 2008, 79:1585-1591.
[27] MOUNTZIARIS P M, MIKOS A G. Modulation of the inflammatoryresponse for enhanced bone tissue regeneration [J]. Tissue engineering.Part B, Reviews, 2008, 14:179-186.
[28] GERSTENFELD L C, CHO T J, KON T, et al. Impairedintramembranous bone formation during bone repair in the absence oftumor necrosis factor-alpha signaling [J]. Cells, tissues, organs, 2001,169:285-294.
[29] JANSSENS S, BEYAERT R. Functional persity and regulation ofdifferent interleukin-1 receptor-associated kinase (irak) family members[J]. Molecular cell, 2003, 11:293-302.
[30] BOYCE B F, XING L, FRANZOSO G, et al. Required and nonessentialfunctions of nuclear factor-kappa B in bone cells [J]. Bone, 1999,25:137-139.
[31] CHANG J, WANG Z, TANG E, et al. Inhibition of osteoblastic boneformation by nuclear factor-kappa B [J]. Nature medicine, 2009,15:682-689.
[32] TABAS I, GLASS C K. Anti-inflammatory therapy in chronic disease:Challenges and opportunities [J]. Science, 2013, 339:166-172.
[33] WIMALAWANSA S J. Nitric oxide: Novel therapy for osteoporosis [J].Expert opinion on pharmacotherapy, 2008, 9:3025-3044.
[34] WIMALAWANSA S J. Nitric oxide and bone [J]. Annals of the New YorkAcademy of Sciences, 2010, 1192:391-403.
[35] BIGHAM-SADEGH A, ORYAN A. Basic concepts regarding fracturehealing and the current options and future directions in managing bonefractures [J]. International wound journal, 2014.
[36] MARSELL R, EINHORN T A. The role of endogenous bonemorphogenetic proteins in normal skeletal repair [J]. Injury, 2009, 40Suppl 3:S4-7.
[37] ORYAN A, ALIDADI S, MOSHIRI A, et al. Bone morphogeneticproteins: A powerful osteoinductive compound with non-negligible sideeffects and limitations [J]. BioFactors, 2014, 40:459-481.
[38] REDLICH K, SMOLEN J S. Inflammatory bone loss: Pathogenesis andtherapeutic intervention [J]. Nature reviews. Drug discovery, 2012,11:234-250.
[39] GARIMELLA R, TAGUE S E, ZHANG J, et al. Expression and synthesisof bone morphogenetic proteins by osteoclasts: A possible path toanabolic bone remodeling [J]. The journal of histochemistry andcytochemistry : official journal of the Histochemistry Society, 2008,56:569-577.
[40] COTTRELL J A, KEANE O, LIN S S, et al. BMP-2 modulatesexpression of other growth factors in a rat fracture healing model [J].Journal of Applied Biomedicine, 2014, 12:127-135.
临床医学硕士论文参考文献二
[1]顾招兵，李明丽，兰国湘等.哺乳仔猪的死亡原闪分析[J].中国倉牧志，2013,49( 16): 65-67.
[2]张明海,张虹虹.母猪产后缺乳症的防治办法[J].今日养猪业，2012，（1):22-24.
[3]毛成荣.辩i正施治母猪产后缺乳[J].山东畜牧兽医，2011,(1):69-70.
[4]彭金霞.产后缺乳症的综合防治[J].黑龙江备牧兽医,2010,(16):65.
[5]李春云，范奍元,李养霞.母猪缺乳症的防治[J].养殖技术顾问，2008，（3):61
[6]宋敏，走晨,陈婉文等.催奶灵注射液对溴隐亭诱发大鼠缺乳的治疗作W[J].华南农业人学学报,2011, 32(2): 119-121.
[7]庄桂玉.母猪产后缺乳的原因与防控[J].农村养姐技术，2013,(9): 17-19.
[8]夏道伦.母猪产后泌乳障碍综合征的发病原因及其应对抬施[J].广东词料，2014,(3): 43-46.
[9]彭代,张洪培，何贵芳等.规模化养猪场母仔猪屮药保健程序[J].屮f1?医学杂志,2008，（1):1-2.
[10]郭春燕，杨继生.母猪产后无乳能的预防与治疗[j].农业技术与装备，2014，（14):74-75，78.
[11]Andrews ZB,Grattan DR. The Roles of Dopamine and the Neurointermediate Lobe of the Pituitaryin the Regulation of Prolactin Secretion During Late Pregnancy in Rats[J]Journal ofNeuroendocrinology, 2004, 16(10): 859-865.
[12]Hoyt RF,Tashjian AH. Immuno-cytochemical Analysis of Prolactin Production ByMonolayer-cultures of Gh3 Rat Anterior-pituitary Tumor-cells .1. Long-term Effects of Stimulationwith Thyrotropin-releasing-hormone (trh)[J]. Anatomical Record, 1980, 197(2): 0-153.
[13]Healy DL. Endometrial Prolactin and Implantation[J]. Baillieres Clinical Obstetrics andGynaecology, 1991, 5(1): 95-105.
[14]Mircheff AK, Warren DW,Wood RL, et al. Prolactin Localization, Binding, and Effects onPeroxidase Release in Rat Exorbital Lacrimal Gland[J]. Investigative Ophthalmology & VisualScience, 1992, 33(3):641-650.
[15]Curlewis JD. Seasonal Prolactin Secretion and Its Role in Seasonal Reproduction a Review[J]_Reproduction Fertility and Development, 1992, 4(1): 1-23.
[16]Lohrke B,KunkeI S,Kowitz J, et al. Prolactin Heterogeneity - a Limitation on the Evaluation ofResults From Prolactin Assays Due to Differences in Immunoassays and the Different Bioactivitiesof Prolactin Forms[J]. European Journal of Clinical Chemistry and Clinical Biochemistry, 1993,31(12):815-827.
[17]Royster IVl,Driscoll P,Kelly PA, et al. The Prolactin Receptor in the Fetal-rat - Cellular-localizationof Messenger-ribonucleic-acid, Immunoreactive Protein, and Ligand-binding Activity and Inductionof Expression in Late-gestation[J]. Endocrinology, 1995，136(9); 3892-3900.
[18]Lotinun S，Limlomwongse L,KrishnamraN. The Study of a Physiological Significance of Prolactinin the Regulation of Calcium Metabolism During Pregnancy and Lactation in Rats[J]. CanadianJournal of Physiology and Pharmacology, 1998, 76(2): 218-228.
[19]Bhatavdekar JM,Patel DD,Chikhlikar PR, et al. Ectopic Production of Prolactin By ColorectalAdenocarcinoma[J]. Diseases of the Colon & Rectum, 2001, 44(1): 119-127.
[20]Bulut SD，Bulut S,Tuzer V，et al. The Effects of Prolactin-raising and Prolactin-sparingAntipsychotics on Prolactin Levels and Bone Mineral Density in Schizophrenic Patients[J].Noropsikiyatri Arsivi-archives of Neuropsychiatry, 2014, 51(3): 205-210.
[21]陈丼华.中两医综合干预产后缺乳理论临床研究[D].中国中科学院，2009.
[22]Farmer C. The Role of Prolactin for Mammogenesis and Galactopoiesis in Swine[J]. LivestockProduction Science, 2001, 70(1): 105-113.
[23]Dalrymple A,Edery M,Jabbour HN. Sequence and Functional Characterisation of the MarmosetMonkey (callithrix Jacchus) Prolactin Receptor: Comparative Homology with the HumanLong-form Prolactin Receptor[J]. Molecular and Cellular Endocrinology, 2000, 167(1): 89-97.
[24]Brisken C,Kaur S,Chavarria TE, et al. Prolactin Controls Mammary Gland Development Via Directand Indirect Mechanisms[J]. Developmental Biology, 1999, 210(1): 96-106.
[25]Coya R,Alvarez CV,Perez F, et al. Effects of Tgf-beta 1 on Prolactin Synthesis and Secretion: anIn-vitro Study[J]. Journal of Neuroendocrinology, 1999，11(5); 351-360.
[26]Buser AC,Gass-handel EK,Wyszomierski SL, et al. Progesterone Receptor Repression ofProlactin/signai Transducer and Activator of Transcription 5-mediated Transcription of theBeta-casein Gene in Mammary Epithelial CelIs[J]. Molecular Endocrinology, 2007, 21(1): 106-125.
[27]Asai-sato M，Nagashima Y,Miyagi E, et al. Prolactin Inhibits Apoptosis of Ovarian Carcinoma CellsInduced By Serum Starvation Or Cisplatin Treatment[J]. International Journal of Cancer, 2005,115(4): 539-544.
[28]Bertucci PY,Quaglino A,Pozzi AG, et al. Glucocorticoid-induced Impairment of Mammary GlandInvolution Is Associated with Stat5 and Stat3 Signaling Modulation[J]. Endocrinology, 2010,151(12): 5730-5740.
[29]薛琪.应用维生素E催乳的疗效观察[J].告林民学，2007，28(3):370.
[30]黄美凌，梁癒霞,刘笑霞等.催产素滴鼻后泌乳量及乳汁成份的观察和分析[J].护理杂志，2000, 35(7): 12-14.
[31]周生芬，李全德.泰必利治疗产后缺乳33例[J].导报，1997,(4): 165.
[32]黄正文,孙蓉,王兰.U服多潘立酮片促进乳汁分泌[J].青岛医药卫生,2002，（2):46-47.
[33]朱艳华,陈冬，李淑珍等.绩毛膜促愧腺激素对过早配种黄牛产后缺乳的临床效果[J].黑龙江动物繁殖，2004,(4): 16.
[34]王成,陈书芳.中兽医.治疗仔猪拉稀和母猪少奶[J].中国动物保健,2012，（8):48-51.
[35]李海江.加味催乳饮治疗母猪产后缺乳症[J].中兽医学杂志，2009,(5): 24.
[36]曹远东,敖淸根，周志等.八珍颗粒对母猪产前产后疾病的临床应用[J].中兽医学杂志，2014，(4); 50.
[37]花丽苑.中々：药在治疗母猪产后疾病的应用[J]./(i殖技术顾问，2010, (7): 113-114.
[38]赵禅娟.生化汤加减在母猪产/5疾病中的临床应厅l[J].黑龙江畜牧兽民，2014,(14):104-105.
[39]张玉杰，.母猪催乳六法[J].中国畜禽种业,2007,(12): 64.
[40]Bole-feysot C,Goffin V，Edery M, et al. Prolactin (prl) and Its Receptor: Actions, SignalTransduction Pathways and Phenotypes Observed in Prl Receptor Knockout Mice[J]. EndocrineReviews, 1998, 19(3): 225-268.
临床医学硕士论文参考文献三
[1] ZUANY-AMORIM C, HASTEWELL J, WALKER C. Toll-like receptors aspotential therapeutic targets for multiple diseases [J]. Nat Rev Drug Discov,2002, 1(10): 797-807.
[2] KAWAI T, AKIRA S. The roles of TLRs, RLRs and NLRs in pathogenrecognition [J]. International immunology, 2009, 21(4): 317-37.
[3] CULLEN T W, GILES D K, WOLF L N, et al. Helicobacter pylori versus thehost: remodeling of the bacterial outer membrane is required for survival in thegastric mucosa [J]. PLoS pathogens, 2011, 7(12): e1002454.
[4] JIN M S, KIM S E, HEO J Y, et al. Crystal structure of the TLR1-TLR2heterodimer induced by binding of a tri-acylated lipopeptide [J]. Cell, 2007,130(6): 1071-82.
[5] KANG J Y, NAN X, JIN M S, et al. Recognition of lipopeptide patterns byToll-like receptor 2-Toll-like receptor 6 heterodimer [J]. Immunity, 2009, 31(6):873-84.
[6] TRIANTAFILOU M, GAMPER F G, LEPPER P M, et al. Lipopolysaccharidesfrom atherosclerosis-associated bacteria antagonize TLR4, induce formation ofTLR2/1/CD36 complexes in lipid rafts and trigger TLR2-induced inflammatoryresponses in human vascular endothelial cells [J]. Cellular microbiology, 2007,9(8): 2030-9.
[7] HAYASHI F, SMITH K D, OZINSKY A, et al. The innate immune response tobacterial flagellin is mediated by Toll-like receptor 5 [J]. Nature, 2001,410(6832): 1099-103.
[8] LUND J, SATO A, AKIRA S, et al. Toll-like receptor 9-mediated recognition ofHerpes simplex virus-2 by plasmacytoid dendritic cells [J]. The Journal ofexperimental medicine, 2003, 198(3): 513-20.
[9] DIEBOLD S S, KAISHO T, HEMMI H, et al. Innate antiviral responses bymeans of TLR7-mediated recognition of single-stranded RNA [J]. Science,2004, 303(5663): 1529-31.
[10] VAN BERGENHENEGOUWEN J, PLANTINGA T S, JOOSTEN L A, et al.TLR2 & Co: a critical analysis of the complex interactions between TLR2 andcoreceptors [J]. J Leukoc Biol, 2013, 94(5): 885-902.
[11] MEDVEDEV A E. Toll-like receptor polymorphisms, inflammatory andinfectious diseases, allergies, and cancer [J]. Journal of interferon & cytokineresearch : the official journal of the International Society for Interferon andCytokine Research, 2013, 33(9): 467-84.
[12] LI J, WANG X, ZHANG F, et al. Toll-like receptors as therapeutic targets forautoimmune connective tissue diseases [J]. Pharmacology & therapeutics, 2013,138(3): 441-51.
[13] VAZ J, AKBARSHAHI H, ANDERSSON R. Controversial role of toll-likereceptors in acute pancreatitis [J]. World journal of gastroenterology : WJG,2013, 19(5): 616-30.
[14] HACKAM D J, GOOD M, SODHI C P. Mechanisms of gut barrier failure inthe pathogenesis of necrotizing enterocolitis: Toll-like receptors throw theswitch [J]. Seminars in pediatric surgery, 2013, 22(2): 76-82.
[15] FALCK-HANSEN M, KASSITERIDI C, MONACO C. Toll-like receptors inatherosclerosis [J]. International journal of molecular sciences, 2013, 14(7):14008-23.
[16] ROH Y S, SEKI E. Toll-like receptors in alcoholic liver disease, non-alcoholicsteatohepatitis and carcinogenesis [J]. J Gastroenterol Hepatol, 2013, 28 Suppl1(38-42.
[17] PRADA P O, COELHO M S, ZECCHIN H G, et al. Low salt intake modulatesinsulin signaling, JNK activity and IRS-1ser307 phosphorylation in rat tissues[J]. The Journal of endocrinology, 2005, 185(3): 429-37.
[18] NIEDZIELSKA I, NIEDZIELSKI Z, TKACZ M, et al. Toll-like receptors andthe tendency of normal mucous membrane to transform to polyp or colorectalcancer [J]. Journal of physiology and pharmacology : an official journal of thePolish Physiological Society, 2009, 60 Suppl 1(65-71.
[19] BELMONT L, RABBE N, ANTOINE M, et al. Expression of TLR9 intumor-infiltrating mononuclear cells enhances angiogenesis and is associatedwith a worse survival in lung cancer [J]. International journal of cancer Journalinternational du cancer, 2014, 134(4): 765-77.
[20] PODDA G, NYIRENDA M, CROOKS J, et al. Innate immune responses in theCNS: role of toll-like receptors, mechanisms, and therapeutic opportunities inmultiple sclerosis [J]. Journal of neuroimmune pharmacology : the officialjournal of the Society on NeuroImmune Pharmacology, 2013, 8(4): 791-806.
[21] BURDELYA L G, BRACKETT C M, KOJOUHAROV B, et al. Central role ofliver in anticancer and radioprotective activities of Toll-like receptor 5 agonist[J]. Proceedings of the National Academy of Sciences of the United States ofAmerica, 2013, 110(20): E1857-66.
[22] LUCAS K, MAES M. Role of the Toll Like receptor (TLR) radical cycle inchronic inflammation: possible treatments targeting the TLR4 pathway [J].Molecular neurobiology, 2013, 48(1): 190-204.
[23] RAJPUT S, VOLK-DRAPER L D, RAN S. TLR4 Is a Novel Determinant ofthe Response to Paclitaxel in Breast Cancer [J]. Molecular cancer therapeutics,2013, 12(8): 1676-87.
[24] LIN Y T, VERMA A, HODGKINSON C P. Toll-Like Receptors and HumanDisease: Lessons from Single Nucleotide Polymorphisms [J]. Curr Genomics,2012, 13(8): 633-45.
[25] SOMMARIVA M, DE CECCO L, DE CESARE M, et al. TLR9 AgonistsOppositely Modulate DNA Repair Genes in Tumor versus Immune Cells andEnhance Chemotherapy Effects [J]. Cancer Res, 2011, 71(20): 6382-90.
[26] KAWAI T, AKIRA S. Toll-like receptors and their crosstalk with other innatereceptors in infection and immunity [J]. Immunity, 2011, 34(5): 637-50.
[27] MIYAKE K. Innate recognition of lipopolysaccharide by CD14 and toll-likereceptor 4-MD-2: unique roles for MD-2 [J]. Internationalimmunopharmacology, 2003, 3(1): 119-28.
[28] CULINA S, BOITARD C, MALLONE R. Antigen-based immune therapeutics 72for type 1 diabetes: magic bullets or ordinary blanks? [J]. Clinical &developmental immunology, 2011, 2011(286248.
[29] LEHUEN A, DIANA J, ZACCONE P, et al. Immune cell crosstalk in type 1diabetes [J]. Nat Rev Immunol, 2010, 10(7): 501-13.
[30] PATTERSON C C, DAHLQUIST G G, GYURUS E, et al. Incidence trends forchildhood type 1 diabetes in Europe during 1989-2003 and predicted new cases2005-20: a multicentre prospective registration study [J]. Lancet, 2009,373(9680): 2027-33.
[31] BACH J F, CHATENOUD L. The hygiene hypothesis: an explanation for theincreased frequency of insulin-dependent diabetes [J]. Cold Spring Harborperspectives in medicine, 2012, 2(2): a007799.
[32] BLUESTONE J A, HEROLD K, EISENBARTH G. Genetics, pathogenesis andclinical interventions in type 1 diabetes [J]. Nature, 2010, 464(7293): 1293-300.
[33] LI M, SONG L, GAO X, et al. Toll-like receptor 4 on islet beta cells sensesexpression changes in high-mobility group box 1 and contributes to theinitiation of type 1 diabetes [J]. Experimental & molecular medicine, 2012,44(4): 260-7.
[34] DEVARAJ S, TOBIAS P, JIALAL I. Knockout of toll-like receptor-4 attenuatesthe pro-inflammatory state of diabetes [J]. Cytokine, 2011, 55(3): 441-5.
[35] DEVARAJ S, DASU M R, PARK S H, et al. Increased levels of ligands ofToll-like receptors 2 and 4 in type 1 diabetes [J]. Diabetologia, 2009, 52(8):1665-8.
[36] ALKANANI A K, REWERS M, DONG F, et al. Dysregulated Toll-likereceptor-induced interleukin-1beta and interleukin-6 responses in subjects atrisk for the development of type 1 diabetes [J]. Diabetes, 2012, 61(10):2525-33.
[37] SADELAIN M W, QIN H Y, LAUZON J, et al. Prevention of type I diabetes inNOD mice by adjuvant immunotherapy [J]. Diabetes, 1990, 39(5): 583-9.
[38] TIAN B, HAO J, ZHANG Y, et al. Upregulating CD4+CD25+FOXP3+regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvantimmunotherapy [J]. Transplantation, 2009, 87(2): 198-206.
[39] CARAMALHO I, RODRIGUES-DUARTE L, PEREZ A, et al. Regulatory Tcells contribute to diabetes protection in lipopolysaccharide-treated non-obesediabetic mice [J]. Scand J Immunol, 2011, 74(6): 585-95.
[40] GULDEN E, IHIRA M, OHASHI A, et al. Toll-like receptor 4 deficiencyaccelerates the development of insulin-deficient diabetes in non-obese diabeticmice [J]. Plos One, 2013, 8(9): e75385.